Twist Bioscience Stock Price, News & Analysis

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Sample ID Kit, designed to track samples in next-generation sequencing (NGS) workflows. This innovation aims to minimize sample mix-ups, reducing the necessity for test re-runs and enhancing data accuracy. It is compatible with Twist NGS workflows, allowing quick identification of samples from whole blood. The kit will be showcased at the American Society of Human Genetics Annual Meeting on October 26, 2022, highlighting its capability of improving precision in genetic research.

Twist Bioscience Corporation (NASDAQ: TWST) has received the Great Place to Work Certification for the second consecutive year in the U.S. and additionally in China, Germany, Singapore, and the United Kingdom. A survey revealed that 85% of employees consider Twist a great workplace, significantly higher than the 57% average. CEO Emily M. Leproust emphasized the importance of company culture and announced the release of their first ESG report to showcase commitment to diversity and inclusion.

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, SVP of Business Development for Data Storage, will present at the JSNN NanoImpacts 2022 conference from October 13-15, 2022 in Greensboro, NC. He will participate in a panel on October 13 and deliver a keynote on DNA data storage on October 14 at 9:00 AM ET. The conference aims to address advancements in synthetic biology and nanomaterials, following the 2018 SemiSynBio Roadmap.

Twist Bioscience (NASDAQ: TWST) has partnered with the Australian Research Council Centre of Excellence in Synthetic Biology (CoESB) to provide researchers with access to a wide range of Twist's DNA synthesis products. This collaboration aims to enhance research capabilities and foster the development of sustainable biobased products. Twist's proprietary technology will support the design of novel organisms for transforming agricultural waste into valuable products, contributing to a sustainable economy in Australia.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at the Baird 2022 Global Healthcare Conference on September 13th at 2:35 p.m. ET in New York. The presentation will be webcast live, and a replay will be available for 30 days. Twist is a leader in synthetic biology, utilizing a proprietary silicon-based technology to manufacture synthetic DNA for various industries, including healthcare and agriculture. The company's focus includes synthetic genes and NGS preparation tools, with future ambitions in DNA data storage and biologics discovery.

Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $56.1 million for 3QFY22, reflecting a 60% increase from $35.0 million in the same quarter of fiscal 2021. Total orders soared 53% to $59.7 million. The company raised its revenue guidance to $203 million for fiscal 2022. Despite growth, a net loss of $60.5 million was recorded, translating to $1.08 per share. R&D expenses rose to $36.8 million, while cash reserves stood strong at $527.6 million.

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Flash Memory Summit from August 2-4, 2022, in Santa Clara, CA. His presentation is scheduled for August 4 from 8:30-9:45 AM PT, focusing on the application of DNA for large-scale data storage solutions. The summit gathers industry leaders to discuss various advancements in data storage technologies. For registration, visit: Flash Memory Summit.

Twist Bioscience (TWST) highlights a critical need for innovative enterprise storage technologies, according to a new white paper. Key points include:

• Projected storage demand could exceed 25 zettabytes by 2030, outpacing available capacity.
• Approximately 75% of stored data is 'cold', rarely accessed, and likely never deleted.
• DNA data storage is proposed as a solution, promising high density, cost efficiency, and sustainability.

The company aims to lead in this space, addressing a projected $7 billion unmet storage demand.

Twist Bioscience Corporation (NASDAQ: TWST) and Biotia, Inc. have received an expanded Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This authorization enhances COVID-19 patient management by allowing for the identification of specific genomic mutations and viral lineages. Originally developed in 2020 and authorized in March 2021, the assay provides crucial insights into evolving variants like Omicron. The assay’s hybridization capture-based method improves mutation detection, aiding clinicians in treatment decisions.